Breast cancer that is triple-negative (TNBC) has a poor prognosis and is highly prone to relapse and metastasis. The specificity of TNBC makes it difficult to determine the standard and best treatment for patients because TNBC does not have three hormone receptors like other types of breast cancer (ER+, PR+ HER2+). Currently, a standard treatment for triple-negative breast cancer is chemotherapy. As well as being effective as a treatment method, novel immunotherapy has also risen in popularity. It is true that there are numerous articles introducing chemotherapy and immunotherapy in detail, but few of these papers compare the two. The purpose of this article is to summarize three common types of chemotherapy and two types of immunotherapies. Furthermore, a comparison based on resistance, toxicity, survival, and response rates shows that immunotherapy has a few advantages over chemotherapy, but it still has some disadvantages. However, a combination of both immunotherapy and chemotherapy is more effective for TNBC patients.
|